The sharp pain drew me out of sleep one misty February morning in 2023. My side felt like a stab wound. Weeks of discomfort had morphed into agony, barely manageable with pain relief. Once at the emergency room, the diagnosis came as a shock: multiple myeloma, a blood cancer known for leaving holes in bones.
Upon leaving the hospital, I turned to the internet. Initial findings were grim, predicting three to five years of survival. This information was soon proven outdated — many patients now live longer due to advancements in treatment, including the controversial drug, Revlimid.
The Unlikely Hero: Revlimid
Revlimid, a derivative of thalidomide, carries a complex history. Thalidomide’s past includes causing birth defects when given to pregnant women in the mid-20th century, leading to its widespread ban. Revlimid, with over $100 billion in sales, has since extended countless lives.
The cost of Revlimid is steep, nearly $1,000 per pill, though production costs just 25 cents. Many can’t afford it, resulting in financial hardship and fueling rising insurance premiums.
A Personal Battle
Reporting on healthcare costs is not new to me. Yet the price of Revlimid was striking, akin to buying a new iPhone or car monthly. Understanding its pricing led me to uncover Celgene’s strategies and regulatory failures that have kept its cost high.
Tiny and Terrifying: Beth Wolmer’s Influence
In 1995, Beth Wolmer’s husband, Ira, was diagnosed with multiple myeloma. They turned to Dr. Bart Barlogie, known for his bold approaches. Despite undergoing intensive treatments, Ira showed no improvement. Desperate, Beth pursued thalidomide under the guidance of Dr. Judah Folkman, whose research suggested its potential against tumors.
“I wanted him alive forever.” — Beth Wolmer
Though thalidomide didn’t work for Ira, it benefited another patient, confirming its unexpected efficacy in treating myeloma.
Celgene’s Approach
Celgene, holder of thalidomide patents, capitalized on its renewed potential. Initial ventures were risky; in the mid-90s, the company faced financial challenges. However, the surprise the success of thalidomide in treating myeloma revitalized Celgene, catapulting its revenue.
Celgene’s strategy included substantial price increases. Revlimid launched at $55,000 annually in 2005 but rose to $70,560 within months after FDA approval for myeloma treatment. This trend of rising costs continued, eventually reaching hundreds of dollars per pill.
The Battle for Affordable Access
Insurance often covers the high costs, but price hikes continue under new ownership by Bristol Myers Squibb. Efforts to hinder generic competition through patent protections and regulatory exploitation have also been noted as key elements in maintaining high prices.
The Human Impact
The steep price of Revlimid has led many patients to financial ruin, often forcing them to forgo necessary treatment. Celgene’s ties with medical professionals and patient advocacy groups have further cemented its influence, drawing criticism and legal challenges.
Long-Term Challenges
As a drug, Revlimid remains both essential and challenging, with side effects and high costs posing significant burdens. Despite its effectiveness, the quest for price transparency and fairness in drug pricing continues, with Revlimid serving as a focal point in the broader healthcare cost debate.
The consequences reach beyond individual patients, affecting overall healthcare expenditures and highlighting the critical need for reform in drug pricing policies.